Tsipi Keren-Lehrer, Compugen: Focusing on in silico predictive discovery of biologics targets for oncology and immunology




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Tsipi Keren-Lehrer, Compugen: Focusing on in silico predictive discovery of biologics targets for oncology and immunology
Released on: February 19, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this interview, filmed at BIO Europe 2013 in Vienna, Paul Larsmon speaks to Tsipi Keren-Lehrer, Vice President, Business Development at Compugen.
  • Summary
  • Transcript
  • Participants
  • Company
In this interview, filmed at BIO Europe 2013 in Vienna, Paul Larsmon speaks to Tsipi Keren-Lehrer, Vice President, Business Development at Compugen. They discuss how Compugen model key biological phenomena such as alternative splicing, protein cleavage and protein interacting segments; integrate and analyze vast quantities of experimental data, both public and proprietary, and systematically predict and select novel product candidates for oncology and immunology. We form R&D collaborations with biopharmaceutical and biotechnology companies to discover novel drug candidates that are of interest to partners (e.g., inhibition of a target of interest and discovery of novel family members).They also discuss how Compugen form co-development collaborations around discoveries already in their portfolio, aiming to further advance these programs towards IND, and provide partners with exclusive licenses for further clinical development and commercialization.
In this interview, filmed at BIO Europe 2013 in Vienna, Paul Larsmon speaks to Tsipi Keren-Lehrer, Vice President, Business Development at Compugen. They discuss how Compugen model key biological phenomena such as alternative splicing, protein cleavage and protein interacting segments; integrate and analyze vast quantities of experimental data, both public and proprietary, and systematically predict and select novel product candidates for oncology and immunology. We form R&D collaborations with biopharmaceutical and biotechnology companies to discover novel drug candidates that are of interest to partners (e.g., inhibition of a target of interest and discovery of novel family members).They also discuss how Compugen form co-development collaborations around discoveries already in their portfolio, aiming to further advance these programs towards IND, and provide partners with exclusive licenses for further clinical development and commercialization.
Tsipi Keren-Lehrer
Compugen
Compugen